Clinical trials: CMV
HIV Infections, Cytomegalovirus
A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.
This was an open-label, controlled study, conducted at US sites to evaluate the anti-inflammatory effectiveness of the study drug letermovir in adults with HIV and asymptomatic cytomegalovirus (CMV) who were on antiretroviral…
- Conditions
- HIV Infections, Cytomegalovirus, CMV
- Trial name
- ELICIT (NCT04840199)
- Testing
- Letermovir Oral Tablet
- Where
- 15 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
CMV Infection, Hematopoietic Stem Cell Transplantation
Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China
In the 30 years of fighting CMV infection, the mortality rate among HSCT patients has significantly reduced. Now, the focus is on improving the prognosis of HSCT patients and preventing CMV infection.
- Trial name
- NCT05789615
- Testing
- Letermovir
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital of Soochow University
CMV Infection, Cytomegalovirus Infections
Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells
The present trial will consist of the treatment of 20 pediatric and adult Hematopoietic Stem Cell Transplantation (HSCT) recipients or immunocompromised participants diagnosed with opportunistic Cytomegalovirus (CMV) infections…
- Conditions
- CMV Infection, Cytomegalovirus Infections, CMV Viremia, Opportunistic Infections
- Trial name
- NCT03798301
- Testing
- CMV-specific T-cells
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Wisconsin, Madison
Cytomegalovirus (CMV)-Positive Recipients, Allogeneic, Hematopoietic Cell Transplant (HCT)
A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
The purpose of the study was to evaluate the efficacy of ASP0113 compared with placebo as measured by a primary composite endpoint of overall mortality and CMV end organ disease (EOD) through 1 year post-transplant.
- Trial name
- HELIOS (NCT01877655)
- Testing
- ASP0113
- Where
- 83 sites in United States, Australia and 9 more
- Volunteers
- 514 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor
The purpose of this study was to evaluate the efficacy of ASP0113 compared to placebo in reducing the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor.
- Trial name
- NCT01974206
- Testing
- ASP0113
- Where
- 53 sites in United States, Australia and 4 more
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Global Development, Inc.
CMV Viremia, CMV
Expansion of Virus-Specific Lymphocytes for Cell Therapy
Infections and reactivation of human cytomegalovirus (CMV), adenovirus, Epstein-barr and polyoma virus infections are frequent causes of morbidity and mortality and are a source of serious complications in patients undergoing…
- Trial name
- NCT06011486
- Testing
- Lymphocyte infusion (ImmuneCellVir-I)
- Where
- Brazil
- Volunteers
- 10 people
- Sponsor
- Hospital Israelita Albert Einstein
CMV Viral Loads in Seropositive Renal Transplant Recipients
Study of CMV in Kidney Transplant Recipients
Using novel CYTOF technology to measure a wide array of innate and adaptive cell proportions and cytokine levels, we plan a pilot study in old (>/=60 years) and young (20-40 years) renal transplant recipients who are…
- Trial name
- NCT02061215
- Testing
- CMV viral load
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
CMV Infection, Persistent CMV Viremia
Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to see how well transfusions of T-cells work in treating CMV. Tcells are a type of white blood cell that helps protect the body from infection.
- Trial name
- NCT02136797
- Testing
- CMVpp65 Specific T-cells
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
CMV
Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality for recipients of allogeneic hematopoietic stem cell transplantation(HSCT).
- Trial name
- INMUNOCELL (NCT04056533)
- Testing
- CMV CTLs
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Cytomegalovirus (CMV) Infection
Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)
The primary objective of this study is to evaluate the pharmacokinetics (PK) of letermovir (LET) in pediatric participants. Participants will be enrolled in the following 3 age groups: Age Group 1: From 12 to <18 years of age…
- Trial name
- NCT03940586
- Testing
- Letermovir oral granules, Letermovir tablet, Letermovir intravenous
- Where
- 40 sites in United States, Australia and 9 more
- Volunteers
- 65 people
- Sponsor
- Merck Sharp & Dohme LLC
Cytomegalovirus (CMV)
A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection
The main aim of the study is to check if maribavir can treat Japanese people with Cytomegalovirus (CMV) infection, and to check side effect from the study treatment and how much maribavir participants can take without getting…
- Trial name
- NCT05137717
- Testing
- Maribavir
- Where
- 20 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Takeda
CMV, Congenital Cmv
Cytomegalovirus Shedding Characteristics in Pregnant Women
The cCHIPS study is a feasibility study for larger scale multi-centre studies and is designed as a single-centre observational cohort, longitudinal, natural history study.
- Conditions
- CMV, Congenital Cmv, Maternal Infections Affecting Fetus or Newborn, Shedding Virus
- Trial name
- cCHIPS (NCT04021628)
- Testing
- No intervention- not applicable
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- St George's, University of London
Cytomegalovirus (CMV)
A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada
The main aim of the study is to assess the clinical outcomes of current CMV management across different regions of the world (Europe [EU] and Canada [CAN]). Data will be collected retrospectively from medical charts.
- Trial name
- NCT05576805
- Where
- 15 sites in Austria, Belgium and 7 more
- Volunteers
- 159 people
- Sponsor
- Takeda
Decompensated Cirrhosis, CMV Reactivation
Prospective Cohort Study of Complications and Outcomes in Cirrhosis
This is a multi-center, nested cohort study intended to investigate the prevalence, risk factors, and outcomes of complications in patients with acutely decompensated cirrhosis, especially focused on Cytomegalovirus (CMV)…
- Conditions
- Decompensated Cirrhosis, CMV Reactivation, Overt Hepatic Encephalopathy
- Trial name
- NCT06374511
- Testing
- Test for CMV reactivation
- Where
- China
- Volunteers
- 660 people
- Sponsor
- Nanfang Hospital, Southern Medical University
CMV Infection or Reactivation After Allogenic HSCT
The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen
The goal of this observational study is to compare the CMV infection and reactivation after allogeneic hematopoietic stem cell transplantation Between Standard Regimen, Methotrexate plus Cyclosporin A, and Post-transplant…
- Trial name
- CMV (NCT06362720)
- Volunteers
- 158 people
- Sponsor
- Siriraj Hospital
CMV Infection
Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection
The two main cytomegalovirus (CMV) prevention strategies are prophylaxis and preemptive therapy. Prophylaxis effectively prevents CMV infection after solid organ transplantation (SOT), but is associated with high rates of…
- Trial name
- NCT06341686
- Testing
- Letermovir 480 MG, Ganciclovir
- Volunteers
- 100 people
- Sponsor
- Hospital do Rim e Hipertensão
Letemovir for the Prevention of CMV Infection After Allo-HSCT
Observational Clinical Study of Letermovir for Preventing CMV Infection After Allo-HSCT
The goal of this observational study is to get a series of clinical data related to the prevention of CMV infection after allo-HSCT with letemovir.
- Trial name
- NCT06306989
- Testing
- Letermovir
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Cao Weijie
Cytomegalovirus (CMV)
A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada
The main aim of the study is to assess the clinical outcomes of current CMV management across different regions of the world (Europe [EU] and Canada [CAN]). Data will be collected retrospectively from medical charts.
- Trial name
- NCT05571137
- Where
- 11 sites in Austria, Belgium and 5 more
- Volunteers
- 118 people
- Sponsor
- Takeda
CMV Infection, CMV Viremia
Real-world CMV Outcomes Among Kidney Transplant Recipients in Brazil
This is a single-center, non-interventional, retrospective study of data, at the level of the individual without identification, extracted from medical records of adult patients undergoing a kidney transplant procedure after 1st…
- Trial name
- NCT06263218
- Where
- Brazil
- Volunteers
- 500 people
- Sponsor
- Hospital do Rim e Hipertensão
CMV Viremia, Immunosuppression-related Infectious Disease
Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted Patients
Marrow transplanted immunocompromised patients with cytomegalovirus (CMV) viral infection will be treated with CMV activated T-Lymphocytes. T-Lymphocytes will be obtained through an apheresis from a compatible donor.
- Trial name
- NCT04018261
- Testing
- Activated T-Lymphocytes
- Where
- 7 sites in Spain
- Volunteers
- 26 people
- Sponsor
- Banc de Sang i Teixits